The South Korea cystic fibrosis (CF) therapeutics market size stood at around USD xx million in 2020 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx% during the forecast period.
Cystic fibrosis (CF) is a lethal genetic disorder, which manifests a variety of symptoms such as chronic productive cough, respiratory difficulty, meconium ileus, malabsorption, failure to thrive, infertility, etc. CF is caused by the mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene located on the long arm of chromosome 7, and over 1000 mutations in this gene have been described to date. CFTR gene encodes a 1,480 amino acid polypeptide, which functions mainly as a chloride channel in epithelial cells of lung, sinuses, pancreas, liver, and reproductive tract.
Incidence of cystic fibrosis is comparatively low in South Korea. Surge in awareness about cystic fibrosis will boost the cystic fibrosis market trend. Increase in R&D investments made by government in the healthcare sector will drive the cystic fibrosis therapeutics market growth. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Unawareness regarding the cystic fibrosis diagnosis of the new-borns impedes the market growth.